Surgical & Medical Instruments & Apparatus·AUSTIN, TX
Summary Financials
PLUS THERAPEUTICS, INC. — SlamSEC
Revenue
$2.7M
FY 2018
Adj. EBITDA
-$12.7M
-472.0% margin
FY 2024
Net Income
-$13.3M
-495.2% margin
FY 2024
EPS (Diluted)
-$4.24
FY 2024
Stock Price
$0.29
-2.1%
2026-03-06
52W Range
$0.16 – $2.08
P/E Ratio
-0.1x
Market Cap
$39.7M
Cash
$8.6M
FY 2024
Total Debt
$3.8M
FY 2023
Net Cash
$4.8M
FY 2023
Enterprise Value
$34.9M
Debt / EBITDA
0.4x
FY 2018
EV / EBITDA
-2.8x
Employees
—
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers.